The purpose of this Master Protocol is to support multiple studies looking at safety and tolerability of different drugs in healthy participants and participants with Alzheimer's disease, and if they remove clumps of protein (amyloid plaque) in the brain in participants with Alzheimer's Disease. Participants will enroll into either A1D-MC-AT01 (NCT07787182) or A1D-MC-AT02 (upcoming).
Are between 18 and 45 years of age
Have a body mass index (BMI) of 18.0 to 32.0 kilograms per square meter (kg/m²)
Are overtly healthy as determined by medical evaluation, including medical history, physical examination, and electrocardiograms (ECGs).
Are between 55-85 years of age
Have currently, or a history of, serious or unstable neurological or psychological disease (except for AD for participants in the AD cohorts).
Have currently, or a history of, significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological diseases.
Have currently, or a history of, allergies to monoclonal antibodies, diphenhydramine, epinephrine, or methylprednisolone.
Have currently, or a history of, clinically significant multiple or severe drug allergies or severe posttreatment hypersensitivity reactions.
Parallel
LY4405094
DrugAdministered intravenously (IV)
LY4405094
DrugAdministered Subcutaneously (SC)
Placebo
DrugAdministered IV
Placebo
DrugAdministered SC
Florbetapir F18
Other interventionAdministered IV
Florbetaben F 18
Other interventionAdministered IV
The number of participants allocated to each substudy
Click on the lead sponsor to view all of their trials.
